Abstract is: Jean C. Emond is the current Thomas S. Zimmer Professor of Surgery at the Columbia University College of Physicians & Surgeons. He is also a Vice Chair in the Department of Surgery and the Chief of Transplantation at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Emond completed both his undergraduate ('75) and medical training ('79) at the University of Chicago. Emond participated in the first living-donor liver transplantation in children in North America. In 1997, Emond established the liver transplant program at Columbia, which has become one of the largest in the United States performing 152 liver transplants in 2006.
| human | Q5 |
| P646 | Freebase ID | /m/02vn844 |
| P27 | country of citizenship | United States of America | Q30 |
| P69 | educated at | University of Chicago | Q131252 |
| Pritzker School of Medicine | Q7245998 | ||
| P108 | employer | Columbia University | Q49088 |
| P735 | given name | Jean | Q7521081 |
| Jean | Q7521081 | ||
| P106 | occupation | physician | Q39631 |
| surgeon | Q774306 | ||
| P21 | sex or gender | male | Q6581097 |
| Q33770113 | A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome-Review of the Literature. |
| Q50015788 | A Liver for a kidney: Ethics of trans-organ paired exchange. |
| Q81282931 | A critical evaluation of hepatic resection in cirrhosis: optimizing patient selection and outcomes |
| Q30429663 | Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost |
| Q46377321 | Adherence to hepatitis B immunoglobulin (HBIG) after liver transplantation |
| Q57999160 | An evaluation of the sensitivity of MRI at detecting hepatocellular carcinoma in cirrhotic patients utilizing an explant reference standard |
| Q49043257 | Analysis of donor risk in living-donor hepatectomy: the impact of resection type on clinical outcome |
| Q44329428 | Analysis of failure in living donor liver transplantation: differential outcomes in children and adults |
| Q40885410 | Anatomic features of reduced-size liver transplant: postsurgical imaging characteristics |
| Q35737361 | Anesthetic considerations during liver surgery. |
| Q48607527 | Anesthetic management of combined heart-liver transplantation |
| Q43571831 | Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants |
| Q46071099 | Auxiliary liver transplant in fulminant failure |
| Q67936832 | Bacterial Infection as a Complication of Liver Transplantation: Epidemiology and Risk Factors |
| Q43742554 | Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency |
| Q88319717 | Big improvements for the smallest recipients |
| Q34085350 | Biliary anatomy as applied to pediatric living donor and split-liver transplantation |
| Q47416271 | Biliary complications in pediatric liver transplantation. A comparison of reduced-size and whole grafts |
| Q46425546 | Biliary complications of reduced-organ liver transplantation |
| Q47961983 | Biliary reconstructive techniques and associated anatomic variants in adult living donor liver transplantations: The adult-to-adult living donor liver transplantation cohort study experience |
| Q33893756 | Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation |
| Q47214457 | Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice |
| Q83292869 | Blockade of the receptor for advanced glycation end products attenuates acetaminophen-induced hepatotoxicity in mice |
| Q92015251 | COVID-19 Associated Hepatitis Complicating Recent Living Donor Liver Transplantation |
| Q93207816 | COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter |
| Q90940665 | Center-Related Bias in MELD Scores Within a Liver Transplant UNOS Region: A Call for Standardization |
| Q57999211 | Changes in hepatic venous morphology with cirrhosis on MRI |
| Q30361159 | Changes in liver and spleen volumes after living liver donation: a report from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL) |
| Q43971343 | Choledochocholedochostomy without a T tube or internal stent in transplantation of the liver |
| Q48603583 | Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors |
| Q37087030 | Combination of liver biopsy with MELD-XI scores for post-transplant outcome prediction in patients with advanced heart failure and suspected liver dysfunction |
| Q38076032 | Complex hepatectomy under total vascular exclusion of the liver: impact of ischemic preconditioning on clinical outcomes. |
| Q30411906 | Computerized assessment of competence-related abilities in living liver donors: the Adult-to-Adult Living Donor Liver Transplantation Cohort Study |
| Q93172830 | Deceased Brain Dead Donor Liver Transplantation and Utilization in the United States: Nighttime and Weekend Effects |
| Q46269536 | Decreased mortality from technical failure improves results in pediatric liver transplantation |
| Q30356729 | Defining long-term outcomes with living donor liver transplantation in North America |
| Q43102040 | Delayed gastric emptying after living donor hepatectomy for liver transplantation |
| Q68007337 | Developments in segmental and living related liver transplantation |
| Q36708746 | Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantation. |
| Q39928858 | Digital imaging of extended criteria donor livers to facilitate placement and utilization |
| Q81366332 | Discovery of diffuse biliary microhamartomas during liver procurement |
| Q39221703 | Donor health assessment after living-donor liver transplantation |
| Q30417895 | Donor morbidity after living donation for liver transplantation |
| Q47546214 | Durable Clinical and Immunologic Advantage of Living Donor Liver Transplantation in Children. |
| Q41817590 | Early Graft Dysfunction in Living Donor Liver Transplantation and the Small for Size Syndrome |
| Q70231135 | Effect of massive transfusion during liver transplantation on rejection and infection |
| Q34667817 | Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients |
| Q58662092 | Ethics of liver transplantation with living donors |
| Q37970458 | Evolution and future perspectives for reduced-size hepatic transplantation |
| Q98654392 | Ex Vivo Resection and Autotransplantation for Conventionally Unresectable Tumors - An 11-year Single Center Experience |
| Q85933037 | Ex vivo pancreaticoduodenectomy and liver autotransplantation for pancreatic head tumor with extensive involvement of the hepatoduodenal ligament |
| Q40142711 | Expanding the Margins: High Volume Utilization of Marginal Liver Grafts Among >2000 Liver Transplants at a Single Institution |
| Q44241402 | Experience with liver transplantation at the University of Chicago |
| Q36711918 | Experience with radical resection in the management of proximal bile duct cancer |
| Q87177375 | Exposure to ionizing radiation during liver transplantation evaluation, waitlist time, and in the postoperative period: a cause for concern |
| Q36540655 | Extended-donor criteria liver allografts |
| Q41125344 | Failure patterns of cryopreserved vein grafts in liver transplantation |
| Q45936051 | Fifty-percent partial liver transplantation in the rat. |
| Q33328295 | Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. |
| Q41194020 | Fully laparoscopic left-sided donor hepatectomy is safe and associated with shorter hospital stay and earlier return to work: A comparative study |
| Q46664890 | Functional analysis of grafts from living donors. Implications for the treatment of older recipients. |
| Q53084366 | Functional distal splenorenal shunt and splenic artery ligation as portal flow modulation in left lobe living donor transplantation. |
| Q91532055 | Global Transplantation COVID Report March 2020 |
| Q80212350 | Ground-glass, polyglucosan-like hepatocellular inclusions: A "new" diagnostic entity |
| Q48244050 | Growth of liver allografts over time in pediatric transplant recipients. |
| Q45059270 | Hepatic Hemodynamics and Portal Flow Modulation: The A2ALL Experience. |
| Q41737931 | Hepatic arterial anatomy as applied to living-donor and split-liver transplantation |
| Q47416265 | Hepatic artery thrombosis in infants. A comparison of whole livers, reduced-size grafts, and grafts from living-related donors |
| Q47433066 | Hypothermic machine preservation attenuates ischemia/reperfusion markers after liver transplantation: preliminary results. |
| Q41673470 | Hypothermic machine preservation facilitates successful transplantation of "orphan" extended criteria donor livers |
| Q47582231 | Hypothermic machine preservation in human liver transplantation: the first clinical series. |
| Q46308739 | Hypothermic machine preservation reduces molecular markers of ischemia/reperfusion injury in human liver transplantation |
| Q89782505 | Identification of an Upper Limit of Tumor Burden for Downstaging in Candidates with Hepatocellular Cancer Waiting for Liver Transplantation: A West-East Collaborative Effort |
| Q76316397 | Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation |
| Q72077430 | Improved results of living-related liver transplantation with routine application in a pediatric program |
| Q30417781 | Incidence and severity of acute cellular rejection in recipients undergoing adult living donor or deceased donor liver transplantation |
| Q44527992 | Incidence and significance of Aspergillus cultures following liver and kidney transplantation |
| Q46410923 | Increased immune responses to regenerating partial liver grafts in the rat. |
| Q79117983 | Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors |
| Q68893563 | Increased utilization of organ donors: transplantation of two recipients from single donor livers |
| Q33561144 | Indications for liver transplantation in pediatric patients. |
| Q67944043 | Innovative use of organs for liver transplantation |
| Q87250709 | International perspectives on advanced liver surgery |
| Q45057468 | Interpretation of liver chemistries in adult donors after living donor liver transplantation |
| Q90496558 | Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies |
| Q39585677 | Leaning to the Left: Increasing the Donor Pool by Using the Left Lobe, Outcomes of the Largest Single-center North American Experience of Left Lobe Adult-to-adult Living Donor Liver Transplantation |
| Q48151069 | Liver Atrophy and Regeneration in Non-Cirrhotic Portal Vein Thrombosis: Effect of Surgical Shunts. |
| Q30361820 | Liver regeneration after living donor transplantation: adult-to-adult living donor liver transplantation cohort study. |
| Q46271042 | Liver transplantation at the University of California, San Francisco |
| Q70741870 | Liver transplantation for fulminant hepatic failure |
| Q38121508 | Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues |
| Q45781627 | Liver transplantation for hepatitis C virus-related cirrhosis. |
| Q46934467 | Liver transplantation for hepatocellular carcinoma: results with preoperative chemoembolization. |
| Q46008851 | Liver transplantation for sclerosing cholangitis |
| Q41926237 | Liver transplantation for the treatment of urea cycle disorders |
| Q41141130 | Liver transplantation in children from living related donors. Surgical techniques and results |
| Q69499818 | Liver transplantation in the management of fulminant hepatic failure |
| Q47183583 | Liver transplantation with reduced-size donor organs |
| Q47177412 | Liver transplantation, including the concept of reduced-size liver transplants in children |
| Q34131955 | Liver transplants from living related donors. |
| Q79743515 | Living donor liver transplantation and hepatitis C |
| Q46153969 | Living related donor liver transplantation: the UCSF experience |
| Q39469727 | Living-donor liver transplantation: current perspective |
| Q40417246 | Longterm outcomes of auxiliary partial orthotopic liver transplantation in preadolescent children with fulminant hepatic failure |
| Q36074384 | Macrochimerism in Intestinal Transplantation: Association With Lower Rejection Rates and Multivisceral Transplants, Without GVHD. |
| Q48010264 | Managing the prevention of retained surgical instruments: what is the value of counting? |
| Q31135457 | Microvascular hepatic artery anastomosis in pediatric segmental liver transplantation: microscope vs loupe |
| Q40651167 | Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients |
| Q48985308 | Molecular expression of acute phase mediators is attenuated by machine preservation in human liver transplantation: preliminary analysis of effluent, serum, and liver biopsies |
| Q38110765 | Morphine three-dimensional T1 gadoxetate MR cholangiography of potential living related liver donors |
| Q38137238 | Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity |
| Q53177109 | Multivisceral ex vivo surgery for tumors involving celiac and superior mesenteric arteries. |
| Q41612147 | Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients |
| Q84136130 | Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma |
| Q48502542 | No country for old livers? Examining and optimizing the utilization of elderly liver grafts. |
| Q44719470 | OKT3 therapy for hepatic allograft rejection. Differential response in adults and children |
| Q44451743 | OKT3 therapy for hepatic allograft rejection: comparison of results in adults and children. |
| Q36708755 | Obesity and microvascular invasion in hepatocellular carcinoma. |
| Q33363388 | One-year morbidity after donor right hepatectomy |
| Q42182957 | Opposing roles of RAGE and Myd88 signaling in extensive liver resection |
| Q34932794 | Optimizing the use of donated cadaver livers: analysis and policy development to increase the application of split-liver transplantation |
| Q80005706 | Organ donation and utilization in the USA |
| Q72094982 | Orthotopic auxiliary liver transplantation for Crigler-Najjar syndrome type 1 |
| Q63977154 | Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium |
| Q30426231 | Outcomes of adult living donor liver transplantation: comparison of the Adult-to-adult Living Donor Liver Transplantation Cohort Study and the national experience |
| Q30417774 | Outcomes of living donor liver transplantation for acute liver failure: the adult-to-adult living donor liver transplantation cohort study |
| Q73181261 | Outflow reconstruction in right hepatic live donor liver transplantation |
| Q33561155 | Overview of reduced-size liver transplantation. |
| Q39227287 | Pathological changes in yearly protocol liver biopsy specimens from healthy pediatric liver recipients |
| Q37090275 | Patterns of Early Allograft Dysfunction in Adult Live Donor Liver Transplantation: The A2ALL Experience. |
| Q68219788 | Patterns of Infection After Pediatric Liver Transplantation |
| Q44996004 | Pediatric liver transplantation at the University of Chicago Hospitals |
| Q35631309 | Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma |
| Q41596322 | Planned exploration of pediatric liver transplant recipients reduces posttransplant morbidity and lowers length of hospitalization |
| Q45936986 | Posttransplant lymphoproliferative disorder presenting in the head and neck. |
| Q46709079 | Posttransplantation growth in pediatric liver recipients |
| Q53112362 | Predicting early allograft failure and mortality after liver transplantation: the role of the postoperative model for end-stage liver disease score. |
| Q81214536 | Predictors of candidate maturation among potential living donors |
| Q42674572 | Predictors of the cost of liver transplantation |
| Q44160798 | Preservation of donor livers with University of Wisconsin solution |
| Q44933910 | Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. |
| Q83667909 | Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors |
| Q43648976 | Prevention of de novo hepatitis B with adefovir plus vaccination in recipients of liver transplants from core antibody-positive donors |
| Q37588906 | Primary follicular lymphoma of the extrahepatic bile duct mimicking a hilar cholangiocarcinoma: case report and review of the literature. |
| Q72816161 | Prior esophageal variceal bleeding does not adversely affect survival after orthotopic liver transplantation |
| Q36922177 | Psychosocial Outcomes 3 to 10 Years After Donation in the Adult to Adult Living Donor Liver Transplantation Cohort Study |
| Q57106692 | Pure Laparoscopic Donor Hepatectomies: Ready for Widespread Adoption? |
| Q35102969 | RAGE Signaling Significantly Impacts Tumorigenesis and Hepatic Tumor Growth in Murine Models of Colorectal Carcinoma |
| Q41853060 | RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB |
| Q46659877 | Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. |
| Q88505069 | Re: The Pursuit of Happiness. The thin line between rights and duties |
| Q51756458 | Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. |
| Q36826974 | Receptor for advanced glycation end products (RAGE) in a dash to the rescue: inflammatory signals gone awry in the primal response to stress |
| Q30427908 | Recipient morbidity after living and deceased donor liver transplantation: findings from the A2ALL Retrospective Cohort Study |
| Q47400677 | Reconstruction of the hepatic vein in reduced size hepatic transplantation |
| Q40588278 | Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story |
| Q41963243 | Reduced-size liver transplantation. Hope for pediatric patient with end-stage liver disease |
| Q39077945 | Reduced-size orthotopic liver transplantation: use in the management of children with chronic liver disease |
| Q85290503 | Reply: To PMID 24954365 |
| Q87020140 | Reply: To PMID 24954365 |
| Q46876175 | Report of the Crystal City meeting to maximize the use of organs recovered from the cadaver donor |
| Q43738900 | Resource utilization of living donor versus deceased donor liver transplantation is similar at an experienced transplant center |
| Q104074134 | Retrospective-Prospective Study of Safety and Efficacy of Sofosbuvir based Direct Acting Antivirals in HIV/HCV Coinfected Participants with Decompensated Liver Disease Pre or Post Liver Transplant |
| Q42662483 | Safety of blood group A2-to-O liver transplantation: an analysis of the United Network of Organ Sharing database |
| Q39032265 | Segmental liver transplantation from living donors. Report of the technique and preliminary results in dogs |
| Q33369312 | Select utilization of obese donors in living donor liver transplantation: implications for the donor pool |
| Q46097254 | Selective surgical management of progressive familial intrahepatic cholestasis (Byler's disease). |
| Q34765518 | Serum adiponectin is associated with worsened overall survival in a prospective cohort of hepatocellular carcinoma patients |
| Q36479527 | Serum lipid expression correlates with function and regeneration following living donor liver transplantation |
| Q69379931 | Shunt surgery with reference to indications for liver transplantation |
| Q68718874 | Small-bowel length and the dose of cyclosporine in children after liver transplantation |
| Q42324426 | Smoking and hepatocellular carcinoma mortality. |
| Q39372379 | Social and Financial Outcomes of Living Liver Donation: A Prospective Investigation Within the Adult-to-Adult Living Donor Liver Transplantation Cohort Study 2 (A2ALL-2). |
| Q35549874 | Split-Liver Transplantation: A Review |
| Q42618285 | Split-liver transplantation in the United States: outcomes of a national survey |
| Q42667958 | Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment |
| Q39824194 | Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. |
| Q41081212 | Strategies for tolerance induction: potential applications in living donor liver transplantation |
| Q68744287 | Successful hepatic transplantation in congenital absence of recipient portal vein |
| Q74262589 | Successful sequential liver and stem cell transplantation for hepatic failure due to primary AL amyloidosis |
| Q73158260 | Surgical anatomy of the left lateral segment as applied to living-donor and split-liver transplantation: a clinicopathologic study |
| Q46502205 | Surgical and anesthetic management of patients undergoing major hepatectomy using total vascular exclusion |
| Q43683086 | Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation |
| Q42633911 | The deceased organ donor with an "open abdomen": proceed with caution |
| Q37949965 | The ethical assessment of innovative therapies: liver transplantation using living donors |
| Q83877745 | The impact of hepatitis C and biliary complications on patient and graft survival following liver transplantation |
| Q46286499 | The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma |
| Q73802582 | The impact of surgical complications after liver transplantation on resource utilization |
| Q40581424 | The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. |
| Q68131479 | The successful management of portal vein thrombosis after hepatic transplantation with a splenorenal shunt |
| Q70999069 | The use of the T tube after orthotopic liver transplantation |
| Q99569052 | Tocilizumab for severe COVID-19 in solid organ transplant recipients: a matched case-control study |
| Q88512973 | Tolerance in clinical liver transplantation: The long road ahead |
| Q41678629 | Total Vascular Exclusion for Major Hepatectomy in Patients With Abnormal Liver Parenchyma |
| Q58283428 | Totally Laparoscopic Full Left Hepatectomy for Living Donor Liver Transplantation in Adolescents and Adults |
| Q52575380 | Transplantation in Value-Based Care for Patients with Renal Failure. |
| Q41939953 | Transplantation of two patients with one liver. Analysis of a preliminary experience with 'split-liver' grafting |
| Q98508052 | Trinational Study Exploring the Early Impact of the COVID-19 Pandemic on Organ Donation and Liver Transplantation at National and Unit Levels |
| Q35133090 | Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation |
| Q70653114 | Use of an absorbable suture material in vascular anastomoses in pediatric liver transplantation |
| Q70582119 | Use of cryopreserved vein allogeneic homografts in liver transplantation |
| Q90031619 | Utilization of Hepatitis C Virus (HCV)-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence? |
| Q43921569 | Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation |
| Q42949676 | Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. |
| Q46271754 | Vasopressin decreases portal vein pressure and flow in the native liver during liver transplantation. |
| Q35118679 | Vasopressin deficiency and vasodilatory state in end-stage liver disease |
| Q91627125 | Whose Liver Is It Anyway? Two Centers Participating in One Living Donor Transplantation |
| Q69004321 | [Heterotopic or orthotopic liver replacement with liver segments?] |
| Q68387265 | [Orthotopic liver transplantation and living donors. An experimental study in the dog] |
| Q68040216 | [Splitting liver transplantation. Orthotopic liver transplantation in two recipients with a single donor liver] |
| Jean Emond | wikipedia |
Search more.